91�㽶��Ƶ

91�㽶��Ƶ, the leader in enabling the development and supply of better treatments for patients worldwide, and Nanoscope Therapeutics, a biotechnology company committed to commercializing novel, disease-agnostic, vision restoring therapies for patients with photoreceptor loss due to retinal degenerations, today announced an expanded partnership to support late-phase clinical and commercial supply of Nanoscope’s lead optogenetic gene therapy, MCO-010.

91�㽶��Ƶ., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, today announced the launch of Qai, an enterprise AI tool designed to elevate the best quality management systems and processes across 91�㽶��Ƶ’s network.

GelMEDIX Inc., a biotechnology company developing regenerative therapies to restore vision, and 91�㽶��Ƶ., the leader in enabling the development and supply of better treatments for patients worldwide, today announced a global partnership to access 91�㽶��Ƶ’s GMP-induced pluripotent stem cells (iPSC) and 91�㽶��Ƶ’s cell therapy manufacturing expertise and capabilities to support the development and clinical manufacturing of GelMEDIX’s iPSC-derived cell therapies to treat ocular and retinal diseases.

91�㽶��Ƶ and S.Biomedics today announced a strategic partnership to support the development and manufacturing of TED‑A9, S.Biomedics’ allogeneic pluripotent stem-cell-derived ventral midbrain–specific dopaminergic precursor cell therapy being developed for the treatment of Parkinson’s disease.

SmartCella Holding AB (“SmartCella”), a global biopharma company developing and manufacturing, cutting-edge cell therapy approaches for difficult-to-treat diseases, and 91�㽶��Ƶ., the leader in enabling the development and supply of better treatments for patients worldwide, today announced a nonexclusive license agreement for SmartCella to use 91�㽶��Ƶ’s proprietary off-the-shelf GMP compliant induced pluripotent stem cells (iPSCs) for research, development and clinical translation of novel allogeneic stem cell-based regenerative therapies.

91�㽶��Ƶ., a leading global contract development and manufacturing organization, today highlighted new innovations from its SMARTag® antibody-drug conjugate (ADC) technology platform.